Cargando…
The emergence of NS5B resistance associated substitution S282T after sofosbuvir‐based treatment
S282T in NS5B is the primary amino acid substitution associated with resistance to sofosbuvir (SOF) but has rarely been detected in patients treated with a SOF‐based regimen. Here, the emergence and fitness of the S282T substitution in virologic failure patients administered SOF‐based regimens acros...
Autores principales: | Gane, Edward J., Metivier, Sophie, Nahass, Ronald, Ryan, Michael, Stedman, Catherine A., Svarovskaia, Evguenia S., Mo, Hongmei, Doehle, Brian, Dvory‐Sobol, Hadas, Hedskog, Charlotte, Lin, Ming, Brainard, Diana M., Yang, Jenny C., McHutchison, John G., Sulkowski, Mark, Younes, Ziad, Lawitz, Eric |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5678900/ https://www.ncbi.nlm.nih.gov/pubmed/29404477 http://dx.doi.org/10.1002/hep4.1060 |
Ejemplares similares
-
Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis
por: Lawitz, Eric, et al.
Publicado: (2015) -
Sofosbuvir/Velpatasvir/Voxilaprevir for patients with HCV who previously received a Sofosbuvir/Velpatasvir‐containing regimen: Results from a retreatment study
por: Ruane, Peter, et al.
Publicado: (2019) -
Adaptation of hepatitis C virus to interferon lambda polymorphism across multiple viral genotypes
por: Chaturvedi, Nimisha, et al.
Publicado: (2019) -
The Future of HCV Therapy: NS4B as an Antiviral Target
por: Dvory-Sobol, Hadas, et al.
Publicado: (2010) -
Detection of a genetic footprint of the sofosbuvir resistance-associated substitution S282T after HCV treatment failure
por: Walker, Andreas, et al.
Publicado: (2017)